Clinical Trials of Metastatic Castration-sensitive Prostate Cancer: Recent Progress and New Horizons

Anis A Hamid; Michael J Morris; Ian D Davis

doi:10.1016/j.euf.2018.12.001

Clinical Trials of Metastatic Castration-sensitive Prostate Cancer: Recent Progress and New Horizons

Eur Urol Focus. 2019 Mar;5(2):165-167. doi: 10.1016/j.euf.2018.12.001. Epub 2018 Dec 14.

Authors

Anis A Hamid¹, Michael J Morris², Ian D Davis³

Affiliations

¹ Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: [email protected].
² Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Monash University, Melbourne, Australia; Eastern Health, Melbourne, Australia.

PMID: 30559064
DOI: 10.1016/j.euf.2018.12.001

Abstract

Recent clinical trials have changed the treatment landscape for metastatic castration-sensitive prostate cancer. Ongoing and future studies using new therapeutic approaches hold the promise of further improving outcomes for patients with advanced prostate cancer.

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Abiraterone Acetate / administration & dosage
Abiraterone Acetate / adverse effects
Abiraterone Acetate / therapeutic use
Androgen Antagonists / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / standards
Combined Modality Therapy / methods
Docetaxel / administration & dosage
Docetaxel / adverse effects
Docetaxel / therapeutic use
Humans
Male
Neoplasm Metastasis / pathology
Neoplasm Metastasis / therapy*
Prostatic Neoplasms, Castration-Resistant / pathology
Prostatic Neoplasms, Castration-Resistant / psychology
Prostatic Neoplasms, Castration-Resistant / secondary*
Prostatic Neoplasms, Castration-Resistant / therapy*
Quality of Life
Radiotherapy / methods
Steroid Synthesis Inhibitors / therapeutic use
Tubulin Modulators / therapeutic use

Substances

Androgen Antagonists
Steroid Synthesis Inhibitors
Tubulin Modulators
Docetaxel
Abiraterone Acetate